All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your GvHD Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2019-06-19T10:18:19.000Z

EHA 2019 | What are the current treatment recommendations for acute GvHD and the promotion of the GvL effect?

By Emily Smith, Robert Zeiser
Featured
Robert Zeiser
Jun 19, 2019
Share:

Bookmark this article

At the 24th Congress of the European Hematology Association (EHA), Robert Zeiser from the University Medical Center Freiburg, Freiburg, DE, discusses the recommendations for the treatment of acute graft-versus-host disease (GvHD) and the promotion of the graft-versus-leukemia (GvL) effect.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a method used commonly in the treatment of acute myeloid leukemia (AML). Chemotherapy is not curative in these patients, so allo-HSCT can provide an immune effect leading to cure. The side effects of allo-HSCT though include infections and GvHD.
GvHD affects mainly the intestine, liver and skin and whilst there are prophylactic treatments available, it is still a risk, especially since GvHD can become steroid-refractory. Robert Zeiser discusses some of the novel approaches tested for GvHD including JAK inhibitors and immunosuppressive approaches.
The conclusion is that this is an exciting field, with those in the field eagerly awaiting the future developments that are coming.

What are the current treatment recommendations for acute GvHD and the promotion of the GvL effect?

More about...
Acute graft-versus-host diseaseAllo-HSCTEHA 2019

Related articles

Add bookmark

Infection prophylaxis for patients with GvHD

During the GvHD Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss infection prophylaxis for patients with GvHD, chaired by Professor Mohamad Mohty.

Aug 16, 2024
Add bookmark

Infection prophylaxis for patients with GvHD

During the GvHD Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss infection prophylaxis for patients with GvHD, chaired by...

Aug 16, 2024
Add bookmark

ASH 2023 abstracts: What’s hot in GvHD?

To help navigate the exciting content presented at the 65th ASH Annual Meeting, the GvHD Hub Steering Committee members provided their recommendations for the top presented abstracts in GvHD.

Dec 1, 2023
Add bookmark

ASH 2023 abstracts: What’s hot in GvHD?

To help navigate the exciting content presented at the 65th ASH Annual Meeting, the GvHD Hub Steering Committee members provided their recommendations for the...

Dec 1, 2023

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox